<DOC>
	<DOCNO>NCT01597596</DOCNO>
	<brief_summary>A study demonstrate comparable safety , efficacy , pharmacokinetics ( PK ) alglucosidase alfa manufacture 160 litre ( L ) 4000 L scale participant diagnose infantile-onset Pompe disease . Participants treat alglucosidase alfa 160 L scale product United States ( US ) 4000 L scale product region outside US .</brief_summary>
	<brief_title>A Noninferiority Study Alglucosidase Alfa Manufactured 160 L 4000 L Scales Treatment Naïve Patients With Infantile-Onset Pompe Disease</brief_title>
	<detailed_description />
	<mesh_term>Glycogen Storage Disease Type II</mesh_term>
	<mesh_term>Glycogen Storage Disease</mesh_term>
	<criteria>The participant 's parent/legal guardian willing able provide sign informed consent . The participant might less equal 12 month age . The participant might document GAA enzyme deficiency blood , skin , muscle tissue . The participant might naïve treatment alglucosidase alfa . The participant crossreactive immunologic material negative . The participant require invasive ventilator support time enrollment . The participant decompensated clinical heart failure . The participant major congenital abnormality , exclude cardiac hypertrophy . The participant clinically significant organ disease ( exclude sign symptom Pompe disease ) . The participant currently receive investigational product . The participant participate another clinical study . The participant and/or patient 's parent/legal guardian unable adhere requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Months</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>